Differential expression and prognostic value of ERCC1 and thymidylate synthase in resected gastric adenocarcinoma

Cancer

Volumn 119, Issue 17, 2013, Pages 3242-3250

  Squires III, Malcolm H ^a   Fisher, Sarah B ^a   Fisher, Kevin E ^a   Patel, Sameer H ^a   Kooby, David A ^a   El Rayes, Bassel F ^a   Staley III, Charles A ^a   Farris III, Alton B ^a   Maithel, Shishir K ^a  

^a EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

biomarkers; ERCC1; gastric adenocarcinoma; thymidylate synthase

Indexed keywords

CAPECITABINE; CISPLATIN; EXCISION REPAIR CROSS COMPLEMENTING PROTEIN 1; FLUOROURACIL; OXALIPLATIN; THYMIDYLATE SYNTHASE; TUMOR MARKER;

ADULT; AGED; ARTICLE; CANCER ADJUVANT THERAPY; CANCER GRADING; CANCER PROGNOSIS; CANCER RADIOTHERAPY; CANCER STAGING; CANCER SURGERY; CANCER SURVIVAL; CLINICAL TRIAL; FEMALE; FOLLOW UP; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LYMPH NODE DISSECTION; LYMPH NODE METASTASIS; LYMPH VESSEL METASTASIS; MAJOR CLINICAL STUDY; MALE; OVERALL SURVIVAL; PARTIAL GASTRECTOMY; PERINEURAL INVASION; PRIORITY JOURNAL; PROTEIN EXPRESSION; STOMACH ADENOCARCINOMA; TOTAL STOMACH RESECTION; TREND STUDY; TUMOR LOCALIZATION; TUMOR VOLUME;

BIOMARKERS; ERCC1; GASTRIC ADENOCARCINOMA; THYMIDYLATE SYNTHASE;

ADENOCARCINOMA; ADULT; AGED; ANALYSIS OF VARIANCE; DNA-BINDING PROTEINS; ENDONUCLEASES; FEMALE; GENE EXPRESSION REGULATION, ENZYMOLOGIC; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; IMMUNOHISTOCHEMISTRY; KAPLAN-MEIER ESTIMATE; LYMPHATIC METASTASIS; MALE; MIDDLE AGED; NEOPLASM GRADING; NEOPLASM INVASIVENESS; PREDICTIVE VALUE OF TESTS; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; STOMACH NEOPLASMS; THYMIDYLATE SYNTHASE; TUMOR MARKERS, BIOLOGICAL;

EID: 84882729595     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.28175     Document Type: Article

References (28)

1. Jemal A, Center MM, DeSantis C, Ward EM,. Global patterns of cancer incidence and mortality rates and trends. Cancer Epidemiol Biomarkers Prev. 2010; 19: 1893-1907.
2. Macdonald JS, Smalley SR, Benedetti J, et al. Chemoradiotherapy after surgery compared with surgery alone for adenocarcinoma of the stomach or gastroesophageal junction. N Engl J Med. 2001; 345: 725-730.
3. Cunningham D, Allum WH, Stenning SP, et al. Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer. N Engl J Med. 2006; 355: 11-20.
4. Lee J, Lim do H, Kim S, et al. Phase III trial comparing capecitabine plus cisplatin versus capecitabine plus cisplatin with concurrent capecitabine radiotherapy in completely resected gastric cancer with D2 lymph node dissection: the ARTIST trial. J Clin Oncol. 2012; 30: 268-273.
5. Bang YJ, Kim YW, Yang HK, et al. Adjuvant capecitabine and oxaliplatin for gastric cancer after D2 gastrectomy (CLASSIC): a phase 3 open-label, randomised controlled trial. Lancet. 2012; 379: 315-321.
6. Slamon DJ, Leyland-Jones B, Shak S, et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med. 2001; 344: 783-792.
7. Andrews J, Yeh P, Pao W, Horn L,. Molecular predictors of response to chemotherapy in non-small cell lung cancer. Cancer J. 2011; 17: 104-113.
8. Gossage L, Madhusudan S,. Current status of excision repair cross complementing-group 1 (ERCC1) in cancer. Cancer Treat Rev. 2007; 33: 565-577.
9. Martin LP, Hamilton TC, Schilder RJ,. Platinum resistance: the role of DNA repair pathways. Clin Cancer Res. 2008; 14: 1291-1295.
10. Maithel SK, Coban I, Kneuertz PJ, et al. Differential expression of ERCC1 in pancreas adenocarcinoma: high tumor expression is associated with earlier recurrence and shortened survival after resection. Ann Surg Oncol. 2011; 18: 2699-2705.
11. Fisher SB, Patel SH, Bagci P, et al. An analysis of human equilibrative nucleoside transporter-1, ribonucleoside reductase subunit M1, ribonucleoside reductase subunit M2, and excision repair cross-complementing gene-1 expression in patients with resected pancreas adenocarcinoma: implications for adjuvant treatment. Cancer. 2013; 119: 445-453.
12. Kwon HC, Roh MS, Oh SY, et al. Prognostic value of expression of ERCC1, thymidylate synthase, and glutathione S-transferase P1 for 5-fluorouracil/ oxaliplatin chemotherapy in advanced gastric cancer. Ann Oncol. 2007; 18: 504-509.
13. Matsubara J, Nishina T, Yamada Y, et al. Impacts of excision repair cross-complementing gene 1 (ERCC1), dihydropyrimidine dehydrogenase, and epidermal growth factor receptor on the outcomes of patients with advanced gastric cancer. Br J Cancer. 2008; 98: 832-839.
14. Sonnenblick A, Rottenberg Y, Kadouri L, et al. Long-term outcome of continuous 5-fluorouracil/cisplatin-based chemotherapy followed by chemoradiation in patients with resected gastric cancer. Med Oncol. 2012; 29: 3035-3038.
15. Fareed KR, Al-Attar A, Soomro IN, et al. Tumour regression and ERCC1 nuclear protein expression predict clinical outcome in patients with gastro-oesophageal cancer treated with neoadjuvant chemotherapy. Br J Cancer. 2010; 102: 1600-1607.
16. Kim KH, Kwon HC, Oh SY, et al. Clinicopathologic significance of ERCC1, thymidylate synthase and glutathione S-transferase P1 expression for advanced gastric cancer patients receiving adjuvant 5-FU and cisplatin chemotherapy. Biomarkers. 2011; 16: 74-82.
17. Baek SK, Kim SY, Lee JJ, Kim YW, Yoon HJ, Cho KS,. Increased ERCC expression correlates with improved outcome of patients treated with cisplatin as an adjuvant therapy for curatively resected gastric cancer. Cancer Res Treat. 2006; 38: 19-24.
18. Heidelberger C,. On the rational development of a new drug: the example of the fluorinated pyrimidines. Cancer Treat Rep. 1981; 65 (suppl 3): 3-9.
19. Maithel SK, Gonen M, Ito H, et al. Improving the clinical risk score: an analysis of molecular biomarkers in the era of modern chemotherapy for resectable hepatic colorectal cancer metastases. Surgery. 2012; 151: 162-170.
20. Tsourouflis G, Theocharis SE, Sampani A, Giagini A, Kostakis A, Kouraklis G,. Prognostic and predictive value of thymidylate synthase expression in colon cancer. Dig Dis Sci. 2008; 53: 1289-1296.
21. Koizumi W, Tanabe S, Azuma M, et al. Impacts of fluorouracil-metabolizing enzymes on the outcomes of patients treated with S-1 alone or S-1 plus cisplatin for first-line treatment of advanced gastric cancer. Int J Cancer. 2010; 126: 162-170.
22. Kim JS, Kim MA, Kim TM, et al. Biomarker analysis in stage III-IV (M0) gastric cancer patients who received curative surgery followed by adjuvant 5-fluorouracil and cisplatin chemotherapy: epidermal growth factor receptor (EGFR) associated with favourable survival. Br J Cancer. 2009; 100: 732-738.
23. Fisher SB, Fisher KE, Patel SH, et al. Excision repair cross-complementing gene-1, ribonucleotide reductase subunit M1, ribonucleotide reductase subunit M2, and human equilibrative nucleoside transporter-1 expression and prognostic value in biliary tract malignancy. Cancer. 2013; 119: 454-462.
24. Edge SB, Byrd DR, Compton CC, Fritz AG, Greene FL, Trotti A, eds. American Joint Committee on Cancer Staging Manual. 7th ed. New York: Springer; 2009.
25. Kim SH, Kwon HC, Oh SY, et al. Prognostic value of ERCC1, thymidylate synthase, and glutathione S-transferase pi for 5-FU/oxaliplatin chemotherapy in advanced colorectal cancer. Am J Clin Oncol. 2009; 32: 38-43.
26. Simon GR, Sharma S, Cantor A, Smith P, Bepler G,. ERCC1 expression is a predictor of survival in resected patients with non-small cell lung cancer. Chest. 2005; 127: 978-983.
27. Olaussen KA, Dunant A, Fouret P, et al. DNA repair by ERCC1 in non-small-cell lung cancer and cisplatin-based adjuvant chemotherapy. N Engl J Med. 2006; 355: 983-991.
28. Simon GR, Schell MJ, Begum M, et al. Preliminary indication of survival benefit from ERCC1 and RRM1-tailored chemotherapy in patients with advanced nonsmall cell lung cancer: evidence from an individual patient analysis. Cancer. 2012; 118: 2525-2531.